Lermed provides blood-based liquid biopsy tools to detect biomarkers for drug efficacy, safety, and patient stratification, enabling more precise clinical trial enrollment. It also offers preclinical stem cell platforms that test drug candidates on patient‑derived models to predict therapeutic performance. By integrating these technologies, Lermed aims to improve success rates of large‑scale clinical trials through a “clinical trial in a dish” workflow.
Funding
Funding not disclosed
Founders
Product
Problem
Drug development for neurodegenerative diseases is hampered by the lack of reliable biomarkers to predict drug efficacy and safety, as well as the difficulty in replicating the complexity of these diseases in traditional preclinical models. This leads to high failure rates in clinical trials and delays the availability of effective treatments for patients.
Solution
Lermed offers a platform that integrates blood-based liquid biopsy and stem cell-based technologies to create personalized in-vitro models for neurodegenerative diseases. Their approach involves identifying relevant biomarkers from patient blood samples and using stem cells to generate patient-derived disease models. These models are then used to assess drug candidate efficacy and safety, stratify patients based on biomarker profiles, and predict clinical trial outcomes. This integrated workflow aims to de-risk drug development and accelerate the discovery of personalized treatments for neurodegenerative conditions.
Target Audience
Lermed's primary customers are pharmaceutical companies developing treatments for neurodegenerative diseases, as well as researchers and clinicians seeking to improve patient stratification and predict drug response.
Features
- Blood-based liquid biopsy platform for biomarker discovery related to drug efficacy and safety.
- Stem cell-based technology for generating patient-derived in-vitro models of neurodegenerative diseases.
- Integrated workflow for conducting "clinical trials in a dish" to leverage preclinical data.
- Patient stratification based on biomarker profiles to identify responders to specific drug candidates.
- Assessment of drug candidate efficiency and safety using patient-specific disease models.
- Identification of companion diagnostics for personalized medicine approaches.